Clinical Scorecard: Exploring General Practitioners' Views on Lipoprotein(a) as a Modifiable Risk Factor for Cardiovascular Disease: A Multi-Method Investigation
At a Glance
Category
Detail
Condition
Elevated Lipoprotein(a) [Lp(a)]
Key Mechanisms
Independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease.
Target Population
Individuals globally, particularly those at high cardiovascular risk.
Care Setting
Primary care, specifically by general practitioners.
Key Highlights
Elevated Lp(a) affects about 20% of the global population but is underdiagnosed.
Only 2 out of 18 GPs routinely test for Lp(a) in high-risk patients.
Barriers to testing include lack of management pathways and low public awareness.
The LILAC-for-Lp(a) educational framework improved GPs' confidence in managing Lp(a).
Universal integration of Lp(a) testing is recommended by multiple lipid and cardiovascular consensus statements.
Guideline-Based Recommendations
Diagnosis
Lp(a) testing should not be limited to high-risk individuals; all individuals should be tested at least once in their lifetime.
Management
Incorporate Lp(a) levels into routine cardiovascular risk assessment.
Monitoring & Follow-up
Conduct cascade testing for inherited lipid disorders such as elevated Lp(a).
Risks
Elevated Lp(a) is an independent risk factor for cardiovascular diseases.
Patient & Prescribing Data
Individuals with elevated Lp(a), particularly those at high cardiovascular risk.
Education and training for GPs are critical for improving management of elevated Lp(a).
Clinical Best Practices
Implement user-friendly decision aids for Lp(a) testing.
Enhance training and education for healthcare professionals on Lp(a).
Integrate Lp(a) into clinical pathways for better management.
